December 3, 2014
Since the late 1990s, new regulations have given us the opportunity to address the needs of the most vulnerable and demanding patients – children. Making medicines for pediatrics adds a whole new dimension to the challenges of formulation and drug delivery, but as our knowledge expands, exciting new developments are in the pipeline.
0 min read
December 2, 2014
A group of researchers have used supercomputers to link proteins to drug side effects (1). Could this computational model be more predictive than current statistical methods?
0 min read
December 2, 2014
Pathways designed to bring medicines to market faster in Europe are not delivering the goods
0 min read
December 2, 2014
Micreos, a biotech based in the Netherlands, has launched the first endolysin registered for human use against methicillin-resistant Staphylococcus aureus. What is an endolysin? Micreos describes it as a “bacteria-killing enzyme” that originates from bacteriophages. We spoke with Bjorn Herpers from the Regional Public Health Laboratory Kennemerland, Haarlem, in the Netherlands to find out more.
0 min read
December 2, 2014
Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).
0 min read
December 2, 2014
Science and business: tenacious partners in a shaky marriage or eternally bound nonidentical twins?
0 min read
December 2, 2014
Electrochemical reaction cells are finding new applications in the pharma R&D lab that could offer big time and cost savings. Here, we share our experiences using electrochemistry with on-line mass spectrometry to study pharmaceutical stability and oxidation products – and explain why we’re electrochemistry converts.
0 min read
December 2, 2014
Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated – especially when products share the same name.
0 min read
December 1, 2014
Upstream processes in biopharma manufacturing are growing ever more efficient; conversely, downstream processing is increasingly a bottleneck. Can a new generation of chromatography techniques and technologies get things moving again?
0 min read
December 1, 2014
The days of “low-hanging fruit” in drug discovery are a thing of the past. Drug candidates are increasingly made up of complex, poorly soluble molecules – and that poses a big challenge: how can we continue to produce effective medicines that meet patient needs?
0 min read
December 1, 2014
How to use a knowledge repository that doesn’t retire or leave you for a competitor.
0 min read
December 1, 2014
Researchers estimate the cost of drug development at over $1 billion, while others say it’s less than $100 million. Who’s right? And how can we accurately determine the true costs?
0 min read
December 1, 2014
The launch of the world’s first biosimilar monoclonal antibody was a big step forward from a regulatory and scientific standpoint. Will there be enough room at the table?
0 min read
December 1, 2014
Could medicines be made more effective with better timing?
0 min read
December 1, 2014
Will FDA fast review and voucher incentives make a difference?
0 min read
December 1, 2014
Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute
0 min read
December 1, 2014
Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?
0 min read
December 1, 2014
The 2014 Access to Medicine index shows progress – but companies remain “conservative”
0 min read
December 1, 2014
The Galactic Grant Competition encourages companies to use the International Space Station for pharmaceutical R&D
0 min read
December 1, 2014
The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...
0 min read
